Apimeds Pharmaceuticals US, Inc. 10-K filing
Filed 2026-05-04 · Report date 2025-12-31 · 2025 FY
Filing metadata
- Accession number
- 0001213900-26-051139
- Form type
- 10-K
- CIK
- 0001894525
- Primary document
- https://www.sec.gov/Archives/edgar/data/1894525/000121390026051139/ea0288344-10k_apimeds.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Apimeds Pharmaceuticals US, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-11.9M | - | - |
| Net Income | $-6.0M | - | - |
| Eps Basic | -0.55 | - | - |
| Eps Diluted | -0.55 | - | - |
| Cash And Equivalents | $1.6M | - | - |
| Total Assets | $164.2M | - | - |
| Total Liabilities | $10.8M | - | - |
| Shareholders Equity | $153.3M | - | - |
| Operating Cash Flow | $-8.9M | - | - |
| Capital Expenditures | $57,333 | - | - |